A
Antiverse
Using machine learning to optimize and develop the current drug discovery process
About Antiverse
Antiverse is a Cardiff AI-driven techbio company designing therapeutic antibodies for hard-to-drug targets such as G-protein coupled receptors and ion channels. Its generative antibody-design platform combines proprietary datasets, machine learning and programmable cell-line engineering in a lab-in-the-loop workflow that designs, builds and validates epitope-specific antibodies in-house, with offices in Boston and Prague and partnerships with multiple top-20 pharma companies. In March 2026 Antiverse raised a $9.3 million Series A led by Soulmates Ventures with Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Kadmos Capital and i&i Biotech Fund, bringing total funding above $20 million, and announced a research agreement with the Cystic Fibrosis Foundation to design antibodies against extracellular CFTR. Sources: Business Wire 3 Mar 2026; FinSMEs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cardiff, United Kingdom
- Employees
- 32
- Open positions
- 2
- Dealroom signal
- 82.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Tech for Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $9.3M | $37M | Soulmates Ventures · Innovation Investment Capital · Development Bank of Wales · Kadmos Capital | ↗ |
| SEED✓Equity / VC | Oct 2024 | $4.6M | $18M | Kadmos Capital · i&i Biotech Fund · Innospark Ventures · AngelHub | ↗ |
Growth signals
Latest recorded traffic for Antiverse is 4K monthly website visits, up 21.2% over the last three months. Antiverse's team grew 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed15 investors entered at this stage
Babraham Bioincubator
Future Planet Capital
Syndicate Room
Wren Capital
Tensor Ventures
Development Bank of Wales
Cambridge Angels
ACF Investors- EPEd Parkinson
Deep Science Ventures
Innospark Ventures
AngelHub
Kadmos Capital
TomorrowScale Ventures
i&i Biotech Fund
Series A3 investors entered at this stage
Soulmates Ventures- ICInnovation Investment Capital
Domino Ventures
Other known investors2 additional known investors
Tech Nation
Martin Drdul
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antiverse on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antiverse’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.